-- Presentations to be webcast on www.exelixis.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 6, 2014--
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will provide
an overview of the company at the following two investor conferences in
Bank of America Merrill Lynch 2014 Health Care Conference, Las Vegas:
The Exelixis presentation is scheduled for 11:40 a.m. EDT / 8:40 a.m.
PDT on Tuesday, May 13.
UBS 2014 Global Healthcare Conference, New York: The Exelixis
presentation is scheduled for 9:00 a.m. EDT / 6:00 a.m. PDT on
Tuesday, May 20.
Each presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to
each presentation to ensure adequate time for any software download that
may be required to listen to the webcast.
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily
on COMETRIQ® (cabozantinib), its wholly-owned inhibitor
of multiple receptor tyrosine kinases. Another Exelixis-discovered
compound, cobimetinib, a highly selective inhibitor of MEK, is being
evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in
a broad development program under a collaboration with Exelixis. For
more information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
Source: Exelixis, Inc.
Susan Hubbard, 650-837-8194
Relations & Corporate Communications